Scrip Podcasts

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 中国带来的变革效应；诺和诺德的新战略；罗氏的抗肥胖新药；安进在舍格伦综合征治疗领域的胜利；以及中国潜在的重磅药物。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WVD7A5RE5VFZZFVTXLSMCTDUGI/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: [email protected]

Show less

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters. 

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WVD7A5RE5VFZZFVTXLSMCTDUGI/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on [email protected].

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；以及中国企业在全球范围内的III期临床试验动态。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: [email protected]

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity. 

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on [email protected].

根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。

Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-7ZFDORUPSJGBDOCM2MFPDOPNT4/

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: [email protected]

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on [email protected].

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/

Pipeline to Patient Productivity Index: https://www.norstella.com/p3i/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: [email protected]